Endocyte — Merger or Acquisition (November 2018)
7 slides from Endocyte's merger presentation, Nov 5, 2018
Slide 1: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” “agreement to acquire,” or s
Slide 2: Significant patient population for prostate cancer
Significant patient population for prostate cancer Prostate Cancer1 (in thousands) Incidence + newly recurrent, stage IV metastatic PC 196 100% Castrate resistant (mCRPC) 88 45% PSMA+ 70 80% Note: Higher percentage of metastatic patients in later lines 2nd Line 75 107% Initial 177Lu-PSMA-617 target
Slide 3: Endocyte uses small molecule ligand to direct radioactive atom to PSMA-expressing cancer cells
Endocyte1 uses small molecule ligand to direct radioactive atom to PSMA-expressing cancer cells RLT that utilizes high affinity targeting ligand to direct potent radiotherapy to prostate cancer cells 177Lu-PSMA-617 pairs PSMA targeting ligand (PSMA-617) to radioactive atom (177Lutetium) “Ligand” is
Slide 4: 177Lu-PSMA-617 has strong Ph2 clinical data
Endocyte1 has strong Ph2 clinical data Sustained response rates in Ph2 trial expansion2 PSA response % PSA PFS and OS correlate to PSA response and compare favorably to historical benchmarks2 PSA PFS 50 patients 50 <30% 13/50 (26%) >30% 37/50 (74%) >50% 31/50 (62%) 00 Overall Survival First 30 patie
Slide 5: Pivotal Ph3 trial design with FDA agreement to rPFS as alternative primary endpoint
Endocyte1 pivotal Ph3 trial design with FDA agreement to OS2 rPFS as alternative primary endpoint to initiated disease primary endpoint to OS as 2:1 Stratified for balance Source: Endocyte Investor Presentation October 2018. 1. The acquisition of Endocyte is subject to customary closing conditions,
Slide 6: Radioligand therapies key takeaways
Radioligand therapies key takeaways Lutathera® belongs to an innovative drug category called radioligand therapy and shows strong launch momentum with Q3 2018 sales of USD 56m 1 The AAA (radioligand therapy) pipeline has projects in development for indications beyond NET 2 Novartis has announced an
Slide 7: Radioligand therapies key takeaways
Radioligand therapies key takeaways 4 Lutathera® belongs to an innovative drug category called radioligand therapy and shows strong launch momentum with Q3 2018 sales of USD 56m 2 The AAA (radioligand therapy) pipeline has projects in development for indications beyond NET 3 Novartis has announced a